Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...

Add Yahoo as a preferred source to see more of our stories on Google. When Dennis Bassett was in his 20s, he saw a stalled car and offered to push it for the owner. As he was assisting, he twisted his ...

The ReActiv8-B Clinical Trial is an international, multi-center, prospective randomized sham controlled blinded trial with one-way crossover, conducted under an Investigational Device Exemption (IDE).

The Food and Drug Administration (FDA) has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back pain. Specifically, the ...

ReActiv8 is an active implantable medical device designed to treat people with chronic low back pain (CLBP). ReActiv8 electrically stimulates the nerves that supply the lumbar multifidus muscle, a key ...

DUBLIN, February 04, 2026--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 ...

Ireland's Mainstay Medical announced that it now has $15 million in debt financing available for the approval and commercialization of its implantable ReActiv8 nerve stimulator to treat chronic lower ...

AURORA, Colo. (CBS4) - It is estimated there are more than 3 million cases of lower back pain in the U.S. every year. Most go away within a few weeks or months, but for some people the pain becomes ...

Mainstay Medical is eyeing European approval for its implantable neuromodulation device, submitting an application for a CE mark in a bid to expand global commercialization for its product. The Dublin ...

When Dennis Bassett was in his 20s, he saw a stalled car and offered to push it for the owner. As he was assisting, he twisted his back and heard a “squishing sound.” “I was helping, being a good ...